A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma-Reference-Cited by-同舟云学术

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

Published:2015-07-15 Issue:19 Volume:121 Page:3481-3490
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Bendell Johanna C.¹,Kelley Robin K.²,Shih Kent C.¹,Grabowsky Jennifer A.²,Bergsland Emily²,Jones Suzanne¹,Martin Thomas²,Infante Jeffrey R.¹,Mischel Paul S.³,Matsutani Tomoo³,Xu Shuichan⁴,Wong Lilly⁴,Liu Yong⁵,Wu Xiaoling⁶,Mortensen Deborah S.⁴,Chopra Rajesh⁵,Hege Kristen⁷,Munster Pamela N.²

Affiliation:

1. Sarah Cannon Research InstituteNashville Tennessee

2. Helen Diller Family Comprehensive Cancer CenterUniversity of CaliforniaSan Francisco California

3. Ludwig Institute for Cancer Research, University of California at San DiegoLa Jolla California

4. Celgene CorporationSan Diego California

5. Celgene CorporationSummit New Jersey

6. Celgene CorporationBerkeley Heights New Jersey

7. Celgene CorporationSan Francisco California

Funder

ProEd Communications, Inc.

Celgene Corporation

Publisher